• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Postoperative radioiodine ablation does not reduce cancer recurrence following thyroidectomy

byNeel MistryandTeddy Guo
July 31, 2025
in Chronic Disease, Endocrinology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The 5-year recurrence-free survival was comparable with ablation and without ablation.

2. Adverse events were comparable in both groups, with no treatment-related deaths.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Differentiated thyroid cancer is often treated with radioiodine ablation after total thyroidectomy, but its benefit in low-risk cases remains unclear. Avoiding ablation could reduce side effects and costs without harming outcomes. This randomized controlled trial aimed to determine if omitting radioiodine ablation is non-inferior to ablation in low-risk patients. The primary outcome of this study was 5-year recurrence-free survival, while key secondary outcome was safety. According to study results, recurrence-free survival was similar in both groups, demonstrating non-inferiority. Although this study was well done, it was limited by low recurrence rates and few higher-risk patients, reducing subgroup analysis power.

Click to read the study in The Lancet

Relevant Reading: Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer

RELATED REPORTS

World Health Organization warns that one in six infections now antibiotic resistant

Increasing cancer incidence rates in younger and older adults worldwide

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

In-depth [randomized controlled trial]: Between Jun 26, 2012, and Mar 18, 2020, 504 patients were assessed for eligibility across 33 UK centers. Included were patients. Included were patients with low-risk differentiated thyroid cancer who had complete resection after total thyroidectomy and pathologic stage pT1–pT3 or pT3a disease. Altogether, 480 patients (249 without ablation and 231 with ablation) were included in the final analysis. The primary outcome of 5-year recurrence-free survival showed non-inferiority for omitting ablation (97.9% without ablation vs. 96.3% with ablation, p for non-inferiority < 0.05). The secondary outcome of safety showed similar adverse event rates between groups, with fatigue, lethargy, and dry mouth being most common. Findings from this study suggest that low-risk patients can safely forgo postoperative radioiodine, reducing hospitalization, side effects, and costs.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: endocrinologyradiationradioiodine ablationradiotherapySurgerythyroid cancerthyroid malignancyThyroidectomy
Previous Post

Retinal scans powered by AI predict stroke risk over a decade

Next Post

Mitapivat improves clinical outcomes in patients with non-transfusion dependent thalassemia

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
The Scan by 2 Minute Medicine®

World Health Organization warns that one in six infections now antibiotic resistant

October 23, 2025
Population-based risk factors and geographical trends identified for vitiligo
Oncology

Increasing cancer incidence rates in younger and older adults worldwide

October 20, 2025
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Endocrinology

Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

August 28, 2025
One-year of Herceptin preferable to two-year regimen
Endocrinology

Vepdegestrant extends progression-free survival in ER-positive, HER2-negative breast cancer

August 28, 2025
Next Post
Ticagrelor reversal agent provides immediate and sustained effect

Mitapivat improves clinical outcomes in patients with non-transfusion dependent thalassemia

Large proportion of late preterm infants and older admitted to the NICU

Preterm infants have increased risk of psychological and physical health comorbidities at adulthood

Microsoft’s MAI‑DxO outperforms doctors on complex case sets

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind November 3rd, 2025
  • Development of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery
  • Paclitaxel-coated devices do not reduce rates of major amputations in chronic limb-threatening ischemia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.